ELIXICON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Elixicon, and when can generic versions of Elixicon launch?
Elixicon is a drug marketed by Forest Labs and is included in one NDA.
The generic ingredient in ELIXICON is theophylline. There are thirty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the theophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Elixicon
A generic version of ELIXICON was approved as theophylline by RHODES PHARMS on September 1st, 1982.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ELIXICON?
- What are the global sales for ELIXICON?
- What is Average Wholesale Price for ELIXICON?
Summary for ELIXICON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 170 |
| Patent Applications: | 3,990 |
| DailyMed Link: | ELIXICON at DailyMed |
US Patents and Regulatory Information for ELIXICON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Forest Labs | ELIXICON | theophylline | SUSPENSION;ORAL | 085502-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
